Corcept Therapeutics Incorporated (CORT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
CORT Revenue Analysis (2014–2025)
As of March 2, 2026, Corcept Therapeutics Incorporated (CORT) generated trailing twelve-month (TTM) revenue of $761.4 million, reflecting strong growth of +11.1% year-over-year. The most recent quarter (Q4 2025) recorded $202.1 million in revenue, down 2.7% sequentially.
Looking at the longer-term picture, CORT's 5-year compound annual growth rate (CAGR) stands at +16.6%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $761.4 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY), CORT has underperformed the peer group in terms of revenue growth. Compare CORT vs AGIO →
Peer Comparison
Compare CORT's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CORTCurrent | $761M | +11.1% | +16.6% | 5.9% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $761.4M | +12.8% | $748.4M | 98.3% | $44.8M | 5.9% |
| 2024 | $675.0M | +39.9% | $664.2M | 98.4% | $137.0M | 20.3% |
| 2023 | $482.4M | +20.0% | $475.9M | 98.7% | $107.3M | 22.2% |
| 2022 | $401.9M | +9.8% | $396.5M | 98.7% | $112.6M | 28.0% |
| 2021 | $366.0M | +3.4% | $360.7M | 98.6% | $124.5M | 34.0% |
| 2020 | $353.9M | +15.5% | $348.3M | 98.4% | $128.2M | 36.2% |
| 2019 | $306.5M | +22.0% | $301.0M | 98.2% | $111.6M | 36.4% |
| 2018 | $251.2M | +57.8% | $246.0M | 97.9% | $89.5M | 35.6% |
| 2017 | $159.2M | +95.8% | $155.6M | 97.8% | $52.9M | 33.2% |
| 2016 | $81.3M | +61.7% | $79.3M | 97.5% | $10.2M | 12.5% |
See CORT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CORT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CORT vs AGIO
See how CORT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CORT's revenue growth accelerating or slowing?
CORT maintains +11.1% revenue growth, in line with its 5-year CAGR of +16.6%. TTM revenue stands at $761M. Growth rate remains consistent with historical average.
What is CORT's long-term revenue growth rate?
Corcept Therapeutics Incorporated's 5-year revenue CAGR of +16.6% reflects the sustained expansion pattern. Current YoY growth of +11.1% is near this long-term average.
How is CORT's revenue distributed by segment?
CORT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.